35 results on '"Valdez, Hernan"'
Search Results
2. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
3. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
4. Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept
5. T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
6. Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment
7. Herpes zoster in psoriasis patients treated with tofacitinib
8. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis
9. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
10. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
11. In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection
12. Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
13. Accessory cell dependent NK cell mediated PBMC IFN-γ production is defective in HIV infection
14. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
15. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic
16. Comprehensive Determinant Mapping of the Hepatitis C-Specific CD8 Cell Repertoire Reveals Unpredicted Immune Hierarchy
17. CD4+ T-Lymphocyte Nadir and the Effect of Highly Active Antiretroviral Therapy on Phenotypic and Functional Immune Restoration in HIV-1 Infection
18. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection
19. ELISPOT Analysis of Hepatitis C Virus Protein-Specific IFN-γ-Producing Peripheral Blood Lymphocytes in Infected Humans with and without Cirrhosis
20. 27582 Abrocitinib improves work productivity through improvement in pruritus and sleep: Results from the JADE MONO-2 study in patients with moderate-to-severe atopic dermatitis (AD)
21. 27603 Rapid itch relief with abrocitinib predicts later skin clearance: A post hoc analysis vs dupilumab and placebo in JADE COMPARE
22. 27550 Durability of response to abrocitinib in patients with moderate-to-severe atopic dermatitis (AD) after treatment discontinuation in a phase 2b trial
23. 27237 Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE
24. 27590 Abrocitinib in the treatment of moderate-to-severe atopic dermatitis refractory to dupilumab treatment: An analysis of JADE-EXTEND, a phase 3 long-term extension study
25. Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study
26. Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
27. Depth and Rapidity of Response With Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis (AD) in JADE COMPARE
28. Pruritus, Sleep, and Productivity: A Post Hoc Analysis of Abrocitinib Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) From JADE MONO-2
29. The utility of clinical and radiographic features in the diagnosis of cytomegalovirus central nervous system disease in AIDS patients
30. Immune reconstitution after combination antiretroviral therapy
31. 16466 Predictors of maintenance of response in patients with moderate to severe atopic dermatitis after oral Janus kinase 1 selective inhibitor abrocitinib interruption
32. 16346 Peak Pruritus Numeric Rating Scale response with abrocitinib in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
33. 15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
34. 15315 Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial
35. Disseminated salmonellosis in a patient with the acquired immunodeficency syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.